Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis.

Trial Profile

Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2014

At a glance

  • Drugs Tabalumab (Primary)
  • Indications Multiple sclerosis
  • Focus Biomarker; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 29 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Mar 2012 Planned number of patients changed from 245 to 500 as reported by European Clinical Trials Database.
    • 24 Jan 2011 Planned end date changed from 1 Jul 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top